StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Xeris Biopharma cash

Cash and short-term investments held at the end of each period.

Xeris Biopharma's cash was $121.75M at Jun 30, 2026. For fiscal 2025 it was $111.04M, up 46.6% from the year before. The highest annual figure on record is $133.79M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$111.04M+46.6%
FY2024Dec 31, 2024$75.74M+4.5%
FY2023Dec 31, 2023$72.45M-42.6%
FY2022Dec 31, 2022$126.31M+23.3%
FY2021Dec 31, 2021$102.43M-23.4%
FY2020Dec 31, 2020$133.79M+585.4%
FY2019Dec 31, 2019$19.52M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$121.75M+105.4%
Q1 FY2026Mar 31, 2026$111.75M+91.2%
Q4 FY2025Dec 31, 2025$111.04M+46.6%
Q3 FY2025Sep 30, 2025$91.60M+32.0%
Q2 FY2025Jun 30, 2025$59.29M-23.6%
Q1 FY2025Mar 31, 2025$58.44M-33.1%
Q4 FY2024Dec 31, 2024$75.74M+4.5%
Q3 FY2024Sep 30, 2024$69.40M+5.2%
Q2 FY2024Jun 30, 2024$77.57M-3.8%
Q1 FY2024Mar 31, 2024$87.35M-8.1%
Q4 FY2023Dec 31, 2023$72.45M-42.6%
Q3 FY2023Sep 30, 2023$65.98M-29.4%
Q2 FY2023Jun 30, 2023$80.67M-27.7%
Q1 FY2023Mar 31, 2023$95.10M-28.0%
Q4 FY2022Dec 31, 2022$126.31M+23.3%
Q3 FY2022Sep 30, 2022$93.43M+0.5%
Q2 FY2022Jun 30, 2022$111.55M+75.4%
Q1 FY2022Mar 31, 2022$132.15M+98.4%
Q4 FY2021Dec 31, 2021$102.43M-23.4%
Q3 FY2021Sep 30, 2021$92.98M+145.4%
Q2 FY2021Jun 30, 2021$63.60M+225.8%
Q1 FY2021Mar 31, 2021$66.60M–
Q4 FY2020Dec 31, 2020$133.79M–
Q3 FY2020Sep 30, 2020$37.89M–
Q4 FY2019Dec 31, 2019$19.52M–

More Xeris Biopharma figures

See a number that looks wrong?